Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Study of IMC-A12 (Anti-Insulin-Like Growth Factor-I Receptor Monoclonal Antibody) in Combination With CCI-779 (Temsirolimus) in Pediatric Patients With Recurrent or Refractory Solid Tumors.

Next Previous
Search
Trial Profile

A Phase I Study of IMC-A12 (Anti-Insulin-Like Growth Factor-I Receptor Monoclonal Antibody) in Combination With CCI-779 (Temsirolimus) in Pediatric Patients With Recurrent or Refractory Solid Tumors.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 09 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cixutumumab (Primary) ; Temsirolimus
  • Indications Solid tumours
  • Focus Adverse reactions; Pharmacokinetics

    • Most Recent Events

    • 22 Mar 2014 Results of an analysis investigating the pharmacokinetic profile of temsirolimus presented at the 115th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
    • 23 May 2012 Planned number of patients changed from 40 to 41 as reported by ClinicalTrials.gov (NCT00880282).
    • 28 Mar 2012 New source identified and integrated (Oregon Health and Science University; IRB00005341).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top